Mohamed Daghi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Daghi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hicham El Otmani
Neurology Department, Ibn Rochd University Hospital Center, Casablanca, Morocco
10 shared publications - Abdelhakim Lakhdar
Research Laboratory of Nervous System Diseases, Neurosensory Disorders & Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco
6 shared publications - Nadia Tahiri Jouti
Laboratory of Cellular and Molecular Inflammatory, Degenerative and Oncologic Pathophysiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco
3 shared publications Abdelhakim Lakhdar
Research Laboratory of Nervous System Diseases, Neurosensory Disorders, and Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, 19, Rue Tarik Ibnou Ziad B.P. 9154, Casablanca, Morocco
2 shared publicationsBouchra El Moutawakil
Neurology Department, Ibn Rochd University Hospital Center, Casablanca, Morocco
2 shared publicationsHicham El Otmani
Neurology Department, Ibn Rochd University Hospital Center, Casablanca, Morocco
2 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Alignment of 5–2–1 criteria with Neurologists' clinical judgment in identifying Advanced Parkinson’s Disease in Morocco: A cross-sectional inter-rater agreement study
Accurate identification of advanced Parkinson’s disease (APD) is crucial for optimizing treatment strategies and ensuring timely consideration of device-aided therapies. The 5–2–1 criteria, derived from an expert consensus using a Delphi-panel approach, have been proposed as a simplified and practical tool for identifying APD. This study evaluates the agreement between Moroccan neurologists’ clinical judgment and the Delphi-panel clinical indicators, with particular focus on the 5–2–1 criteria. A cross-sectional study was conducted over 9 months across 15 private and public facilities in five cities in the Casablanca–Settat region. Neurologists independently determined APD status, which was compared with classifications based on the 5–2–1 criteria and the remaining Delphi-panel indicators. The 5–2–1 criteria were defined by the presence of at least one of the following: ≥5 daily doses of oral levodopa, ≥ 2 h of “off” time per day, or ≥ 1 h of troublesome dyskinesia. Agreement was evaluated with Cohen’s kappa (κ). A total of 370 patients with Parkinson’s disease were included (mean age 65.1 ± 10.7 years; 50.5% male). The 5–2–1 criteria classified 44.6% of patients (95% CI: 39.5%–49.8%) as having APD, while neurologists identified 43.2% (95% CI: 38.3%–48.3%). The two assessments aligned in 73% of cases, indicating moderate agreement (κ = 0.48; 95% CI: 0.43–0.53). The highest agreement was observed when at least two 5–2–1 criteria were met (κ = 0.73; 95% CI: 0.69–0.77), with 90.6% sensitivity and 83.8% specificity, outperforming the standard 5–2–1 classification in terms of specificity (55.2%). Among individual criteria, levodopa dosing ≥ 5 times daily showed the highest agreement (κ = 0.71; 95% CI: 0.67–0.75). The 5–2–1 criteria, particularly when refined to a two-criteria threshold, represent a reliable and practical approach for identifying APD and facilitating timely referral for advanced therapies in Morocco.
- 27 March 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessAlignment of 5–2–1 criteria with Neurologists' clinical judgment in identifying Advanced Parkinson’s Disease in Morocco: A cross-sectional inter-rater agreement study
Accurate identification of advanced Parkinson’s disease (APD) is crucial for optimizing treatment strategies and ensuring timely consideration of device-aided therapies. The 5–2–1 criteria, derived from an expert consensus using a Delphi-panel approach, have been proposed as a simplified and practical tool for identifying APD. This study evaluates the agreement between Moroccan neurologists’ clinical judgment and the Delphi-panel clinical indicators, with particular focus on the 5–2–1 criteria. A cross-sectional study was conducted over 9 months across 15 private and public facilities in five cities in the Casablanca–Settat region. Neurologists independently determined APD status, which was compared with classifications based on the 5–2–1 criteria and the remaining Delphi-panel indicators. The 5–2–1 criteria were defined by the presence of at least one of the following: ≥5 daily doses of oral levodopa, ≥ 2 h of “off” time per day, or ≥ 1 h of troublesome dyskinesia. Agreement was evaluated with Cohen’s kappa (κ). A total of 370 patients with Parkinson’s disease were included (mean age 65.1 ± 10.7 years; 50.5% male). The 5–2–1 criteria classified 44.6% of patients (95% CI: 39.5%–49.8%) as having APD, while neurologists identified 43.2% (95% CI: 38.3%–48.3%). The two assessments aligned in 73% of cases, indicating moderate agreement (κ = 0.48; 95% CI: 0.43–0.53). The highest agreement was observed when at least two 5–2–1 criteria were met (κ = 0.73; 95% CI: 0.69–0.77), with 90.6% sensitivity and 83.8% specificity, outperforming the standard 5–2–1 classification in terms of specificity (55.2%). Among individual criteria, levodopa dosing ≥ 5 times daily showed the highest agreement (κ = 0.71; 95% CI: 0.67–0.75). The 5–2–1 criteria, particularly when refined to a two-criteria threshold, represent a reliable and practical approach for identifying APD and facilitating timely referral for advanced therapies in Morocco.
- Open Access
- 18 September 2025
- Published by SAGE Publications in Journal of Patient Experience
- Vol. 12
Knowledge of Parkinson's Disease, Perceptions of Deep Brain Stimulation, and Attitudes Toward Its Use Among Patients in Morocco: A Cross-Sectional Study
Parkinson's disease (PD) is a chronic neurodegenerative disorder requiring informed decision making, especially regarding advanced treatments such as deep brain stimulation (DBS). However, patient knowledge and perceptions in low-resource settings like Morocco remain poorly understood. This study assessed PD patients’ knowledge and attitudes/perceptions toward DBS in Morocco. A cross-sectional study was conducted among PD patients in 5 cities in the Casablanca-Settat region. Data were collected using a 7-item PD knowledge tool and a DBS attitudes/perceptions questionnaire. A total of 370 patients were recruited, with a mean PD knowledge score of 4.5 out of 7, with higher scores linked to greater education. Only 31.9% had heard of DBS, and 39.4% were willing to undergo it if recommended. Willingness was higher among patients from the private sector, those with longer disease duration, and those at advanced stages. A common misconception was that DBS cures PD (25.9%). Barriers to DBS access included high cost, fear of surgery, lack of specialists, and insufficient information. Gaps in PD knowledge and misconceptions about DBS persist, highlighting the need for targeted educational initiatives in Morocco.
- 18 September 2025
- Published by SAGE Publications in Journal of Patient Experience
- Vol. 12
Open AccessKnowledge of Parkinson's Disease, Perceptions of Deep Brain Stimulation, and Attitudes Toward Its Use Among Patients in Morocco: A Cross-Sectional Study
Parkinson's disease (PD) is a chronic neurodegenerative disorder requiring informed decision making, especially regarding advanced treatments such as deep brain stimulation (DBS). However, patient knowledge and perceptions in low-resource settings like Morocco remain poorly understood. This study assessed PD patients’ knowledge and attitudes/perceptions toward DBS in Morocco. A cross-sectional study was conducted among PD patients in 5 cities in the Casablanca-Settat region. Data were collected using a 7-item PD knowledge tool and a DBS attitudes/perceptions questionnaire. A total of 370 patients were recruited, with a mean PD knowledge score of 4.5 out of 7, with higher scores linked to greater education. Only 31.9% had heard of DBS, and 39.4% were willing to undergo it if recommended. Willingness was higher among patients from the private sector, those with longer disease duration, and those at advanced stages. A common misconception was that DBS cures PD (25.9%). Barriers to DBS access included high cost, fear of surgery, lack of specialists, and insufficient information. Gaps in PD knowledge and misconceptions about DBS persist, highlighting the need for targeted educational initiatives in Morocco.
- Open Access
- 1 September 2025
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 16 (5) , 941-948
Subthalamic Nucleus Deep Brain Stimulation in Early-onset Parkinson’s Disease: Clinical Outcomes in LRRK2 Mutation Carriers Compared to Non-Carriers
Introduction: Subthalamic nucleus deep brain stimulation (STN-DBS) is an established treatment for early-onset Parkinson’s disease (EOPD). While the effect of STN-DBS on patients with LRRK2 G2019S mutation has been largely investigated, data specific to EOPD patients with this mutation remain scarce. This study examines the impact of the LRRK2 G2019S ...
- 1 September 2025
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 16 (5) , 941-948
Open AccessSubthalamic Nucleus Deep Brain Stimulation in Early-onset Parkinson’s Disease: Clinical Outcomes in LRRK2 Mutation Carriers Compared to Non-Carriers
Introduction: Subthalamic nucleus deep brain stimulation (STN-DBS) is an established treatment for early-onset Parkinson’s disease (EOPD). While the effect of STN-DBS on patients with LRRK2 G2019S mutation has been largely investigated, data specific to EOPD patients with this mutation remain scarce. This study examines the impact of the LRRK2 G2019S ...
- 24 March 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 15 (2-3) , 65-76
Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study
This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG). We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility. This study included 370 patients with Parkinson's disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p < 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038). Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.
- 24 March 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 15 (2-3) , 65-76
Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study
This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG). We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility. This study included 370 patients with Parkinson's disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p < 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038). Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.
- Open Access
- 31 January 2025
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 18 (1) , 106-107
Barriers to Accessing Deep Brain Stimulation for Parkinson’s Disease Patients in Morocco
Barriers to Accessing Deep Brain Stimulation for Parkinson’s Disease Patients in Morocco
- 31 January 2025
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 18 (1) , 106-107
Open AccessBarriers to Accessing Deep Brain Stimulation for Parkinson’s Disease Patients in Morocco
Barriers to Accessing Deep Brain Stimulation for Parkinson’s Disease Patients in Morocco
- 3 January 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 236, 108113
Deep brain stimulation for movement disorders treatment in Africa: The current status, outcomes, and challenges
- 3 January 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 236, 108113
Deep brain stimulation for movement disorders treatment in Africa: The current status, outcomes, and challenges
- 1 December 2023
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 13 (6) , 335-350
An Overview of the Worldwide Distribution of LRRK2 Mutations in Parkinson’s Disease
Parkinson's disease (PD) is a neurodegenerative disorder with significant genetic influence. The LRRK2 gene is a major genetic contributor, particularly the Gly2019Ser mutation. This focused review...
- 1 December 2023
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 13 (6) , 335-350
An Overview of the Worldwide Distribution of LRRK2 Mutations in Parkinson’s Disease
Parkinson's disease (PD) is a neurodegenerative disorder with significant genetic influence. The LRRK2 gene is a major genetic contributor, particularly the Gly2019Ser mutation. This focused review...
- Open Access
- 10 August 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (6) , 2447
Correction to: RBD and hyposmia in Moroccan patients with a synucleinopathy: prevalence and the timing of occurrence in a large cohort
- 10 August 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (6) , 2447
Open AccessCorrection to: RBD and hyposmia in Moroccan patients with a synucleinopathy: prevalence and the timing of occurrence in a large cohort
- 12 April 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (6) , 2229-2233
RBD and hyposmia in Moroccan patients with a synucleinopathy: prevalence and the timing of occurrence in a large cohort
Introduction Rapid Eye Movement Sleep Behavior Disorder (RBD) and hyposmia are common in synucleinopathies and they tend to occur in connection to the prodromal development of these disorders. In this study, we sought to determine the prevalence of RBD and hyposmia and the timeline of their occurrence in a large cohort of Moroccan patients. Methods We recruited 734 consecutive patients with synucleinopathy and tauopathy at Ibn Rochd University Hospital of Casablanca. A group of 100 healthy controls was also recruited. We relied on a questionnaire to collect general characteristics and clinical data filled by the patient and his companion under the supervision of a qualified health professional. Results The study included 697 patients with PD, 37 with DLB and 10 had a tauopathy disorder (PSP or CBD). The proportion of patients who have RBD was 52% in PD, 100% in DLB, 0% in tauopathies and 12% among healthy controls. Hyposmia symptom was found in 47% of patients with PD, 68% in patients with DLB, 0% in tauopathy patients and in 10% of healthy controls. Moreover, 46% of PD patients and 75% of DLB patients developed RBD during the prodromal phase. Meanwhile, hyposmia occurred in association with the prodromal phase among 67% of PD cases and 85% of DLB patients. Conclusion RBD and hyposmia are both prevalent among Moroccan patients with synucleinopathy and they occur frequently during the prodromal phase. Identifying these premotor signs will improve early and differential diagnosis and enhance our understanding of how a specific synucleinopathy progresses.
- 12 April 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (6) , 2229-2233
RBD and hyposmia in Moroccan patients with a synucleinopathy: prevalence and the timing of occurrence in a large cohort
Introduction Rapid Eye Movement Sleep Behavior Disorder (RBD) and hyposmia are common in synucleinopathies and they tend to occur in connection to the prodromal development of these disorders. In this study, we sought to determine the prevalence of RBD and hyposmia and the timeline of their occurrence in a large cohort of Moroccan patients. Methods We recruited 734 consecutive patients with synucleinopathy and tauopathy at Ibn Rochd University Hospital of Casablanca. A group of 100 healthy controls was also recruited. We relied on a questionnaire to collect general characteristics and clinical data filled by the patient and his companion under the supervision of a qualified health professional. Results The study included 697 patients with PD, 37 with DLB and 10 had a tauopathy disorder (PSP or CBD). The proportion of patients who have RBD was 52% in PD, 100% in DLB, 0% in tauopathies and 12% among healthy controls. Hyposmia symptom was found in 47% of patients with PD, 68% in patients with DLB, 0% in tauopathy patients and in 10% of healthy controls. Moreover, 46% of PD patients and 75% of DLB patients developed RBD during the prodromal phase. Meanwhile, hyposmia occurred in association with the prodromal phase among 67% of PD cases and 85% of DLB patients. Conclusion RBD and hyposmia are both prevalent among Moroccan patients with synucleinopathy and they occur frequently during the prodromal phase. Identifying these premotor signs will improve early and differential diagnosis and enhance our understanding of how a specific synucleinopathy progresses.